The researchers used DNA methylation profiles to define 82 central nervous system tumor classes, some of which differed from WHO tumor classes.
The companies will join their respective technologies into a precision oncology testing and analysis offering.
The companies also agreed to establish a working group to explore the development of standard formulas and definitions for the validation of genomic profiling assays.
The researchers said their study uncovered an unmet need that could be addressed by changing how genetic counseling is included in clinical practice.
The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.
The firm's Guardant360 assay will be used first to test patients for ERBB2 mutations, then guide patients to a variety of treatment arms.
The company has received a subpoena from HHS' OIG as part of an investigation into possible improper billing of its hereditary cancer tests to Medicare and Medicaid.
The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
Researchers used a capture Hi-C strategy to identify candidate target genes and pathways at dozens of loci previously linked to breast cancer susceptibility.
The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.
A proteomic and targeted exome sequencing study of diffuse-type gastric cancer led to proteomic subtypes with distinct mutation, survival, and potential treatment patterns.
The companies will develop an assay and software package for Thermo's cancer research product portfolio.
The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.
The company plans to grow its business based on the FDA approval and preliminary national coverage determination for its FoundationOne CDx test last year.
The company fell short of Wall Street expectations on the top and bottom lines and said it plans on making some significant changes for 2018, including shutting down its liquid biopsy testing.
Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.
For full-year 2017, the company reported $152.9 million in revenues, up 31 percent over 2016.
A study reported this week that measuring changes in the numbers of specific circulating tumor DNA mutations can rapidly identify breast cancer patients who will have better outcomes.
FDA's blessing for 23andMe's test that gauges select BRCA1/2 variants has the cancer community worried about whether consumers will understand its limitations.
The Israeli biotechnology firm hopes that a successful outcome of the study with Centre Léon-Bérard will raise its profile among oncologists.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.